Brief: OSE Immunotherapeutics/Lusvertikimab: Positive Review from DSMB On Phase 2 Clinical Trial in Ulcerative Colitis

Ose Immunotherapeutics SA

06/07/2023 06:36

July 6 (Reuters) - OSE Immunotherapeutics SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS ANNOUNCES FOR LUSVERTIKIMAB, ITS
ANTI-IL-7 RECEPTOR ANTAGONIST:
    * POSITIVE REVIEW FROM DRUG SAFETY MONITORING BOARD (DSMB)
ON
ONGOING PHASE 2 CLINICAL TRIAL IN ULCERATIVE COLITIS.
    * POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION FROM EUROPEAN
MEDICINES AGENCY IN TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA.
    * COMPANY'S PRIMARY AND STRATEGIC FOCUS REMAINS CLINICAL
EVALUATION OF LUSVERTIKIMAB IN THIS ONGOING ULCERATIVE COLITIS
PHASE 2 STUDY WITH END OF ACCRUAL EXPECTED IN FOLLOWING MONTHS

Source text for Eikon:  ID:nBw4S6jc0a 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))